Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02223312 | Therapy for Progressive and/or Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Kiromic BioPharma Inc.INDUSTRY | 0 | Aug 28, 2018 | clinicaltrials |
| NCT02632903 | Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study | withdrawn | Phase 2 | 0 | Children's Hospital of Eastern OntarioOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02545361 | Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Kahr MedicalINDUSTRY | 0 | Aug 16, 2018 | clinicaltrials |
| NCT02986451 | Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03227432 | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT02672358 | Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2018 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT03297463 | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03370159 | CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03240393 | Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT02943603 | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | withdrawn | Phase 2 | 0 | Weijing Sun, MD, FACPOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01610544 | 18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 5, 2018 | clinicaltrials |
| NCT02014545 | Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 2, 2018 | clinicaltrials |
| NCT02718755 | Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 26, 2018 | clinicaltrials |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 21, 2018 | clinicaltrials |
| NCT02985333 | Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT03023904 | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 25, 2018 | clinicaltrials |
| NCT03241017 | Durvalumab in DLBCL After Autologous Transplant(IDA-D) | withdrawn | Phase 2 | 0 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Apr 9, 2018 | clinicaltrials |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | withdrawn | Phase 1 / Phase 2 | 0 | Joanne JeterOTHER | 0 | Apr 5, 2018 | clinicaltrials |
| NCT02204020 | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS(UPCI 13-165) | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT03004105 | MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 16, 2018 | clinicaltrials |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | withdrawn | Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02856178 | Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients(SAFEGUARD) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT03036046 | Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia(SAFEGUARDFP) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00003512 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01332617 | Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | withdrawn | Phase 2 | 0 | University of LouisvilleOTHER | 0 | Dec 29, 2017 | clinicaltrials |
| NCT02977689 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Dec 20, 2017 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | withdrawn | Phase 2 | 0 | Delcath Systems Inc.INDUSTRY | 1 | Dec 18, 2017 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT03130764 | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Dec 6, 2017 | clinicaltrials |
| NCT02765997 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2018source: clinicaltrials